9-cis Retinoic Acid Pellets for Lymphedema Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for lymphedema, particularly post-surgical lymphedema, are limited by their effectiveness, cost, and patient adherence, with no curative therapies available.
Innovation Solution
The use of 9-cis retinoic acid (9-cis RA) in an implantable, single-use pellet for sustained drug delivery to promote lymphangiogenesis and reduce post-surgical lymphedema.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conservative management (combined decongestive therapy) is used for lymphedema, then symptomatic relief is achieved, but patient adherence is poor due to time-consuming and costly treatment
Solution Approach 1:
The patent applies preliminary action by administering 9-cis retinoic acid before surgical procedures to prevent lymphedema formation. The drug is given preoperatively and postoperatively to stimulate lymphangiogenesis during the critical window when lymphatic vessels are regenerating, thereby preventing edema before it develops rather than treating it after surgery
Solution Approach 2:
The patent replaces the mechanical manual lymphatic drainage component of conservative therapy with a pharmacologic approach. Instead of requiring patients to perform or receive manual drainage procedures, the treatment uses 9-cis retinoic acid to stimulate natural lymphatic vessel growth and function, substituting a chemical mechanism for a mechanical one
2Reliability
If growth factors (VEGF-C, VEGF-D) are used to stimulate lymphangiogenesis, then lymphatic vessel formation is enhanced, but tumor metastasis is promoted
Solution Approach 1:
The patent applies parameter changes by switching from using growth factors (VEGF-C, VEGF-D) to using retinoic acid (9-cis RA) as the pharmacologic agent. This parameter change in the chemical structure and mechanism of action of the drug allows for stimulation of lymphangiogenesis without the harmful effect of promoting tumor metastasis, as retinoic acid does not have the same pro-metastatic properties as VEGF growth factors
3Reliability
If daily intraperitoneal injections of 9-cis RA are administered, then lymphedema prevention is achieved, but treatment complexity and patient burden increase
Solution Approach 1:
The patent applies this principle by using a disposable oral formulation of 9-cis retinoic acid that can be easily administered and discarded after use. The oral tablet or capsule form eliminates the need for repeated intraperitoneal injections, making the treatment simpler, less invasive, and more suitable for outpatient use while maintaining effectiveness
Data Source
AI summary
A method of treating post-surgical edema includes a step of administering an effective amount of a pharmaceutical composition to a subject identified a risk of post-surgical edema. The pharmaceutic composition include a retinoic acid component selected from the group consisting of 9-cis retinoic acid, geometric isomers of 9-cis retinoic acid, metabolites of 9-cis retinoic acid, substituted derivatives thereof, and combinations thereof. An implantable pellet including the retinoic acid component is also provided.